← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Trophogen, Inc.
Rockville, MD
$15,971,615
Total funding
14
Grants
Funding over time
peak $2.5M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$15,821,615 · 13
FDA$150,000 · 1
By mechanism
R44$14,894,389 · 8
R43$1,077,226 · 6
Investigators at Trophogen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Superactive Analogs of FSH for Human Infertility$972,062
R44 · FY2012 · HD
Development of Superactive Analogs of FSH for Human Infertility$972,062
R44 · FY2013 · HD
Development of Superactive Analogs of FSH for Human Infertility$972,062
R44 · FY2011 · HD
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility$942,701
R44 · FY2019 · HD
Recombinant Human TSH Superagonists for Imaging of Thyroid Cancer$910,851
R44 · FY2011 · DK
Development of Superagonist Analogs of Recombinant Human TSH for Imaging and Ther$894,568
R44 · FY2008 · DK
Development of Superagonist Analogs of Recombinant Human TSH for Imaging and Ther$880,167
R44 · FY2009 · DK
Recombinant Human TSH Superagonists for Imaging of Thyroid Cancer$829,058
R44 · FY2010 · DK
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility$825,420
R44 · FY2018 · HD
Novel High Affinity VEGF Analogs For Targeted Imaging of Thyroid Cancer$825,054
R44 · FY2014 · CA
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$778,770
R44 · FY2019 · CA
Novel High Affinity VEGF Analogs For Targeted Imaging of Thyroid Cancer$765,782
R44 · FY2015 · CA
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle$733,166
R44 · FY2019 · HD
Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle$727,601
R44 · FY2020 · HD
Development of Superactive Analogs of Follice Stimulating Hormone (FSH)$616,035
R44 · FY2007 · DK
Development of Superactive Analogs of FSH$601,233
R44 · FY2006 · DK
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$433,685
R44 · FY2020 · CA
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$345,085
R44 · FY2021 · CA
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility$299,999
R44 · FY2017 · HD
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.$285,070
R44 · FY2018 · CA